The authors discuss that preclinical testing of drugs in such nasal epithelial cell cultures of CF patients should be performed to provide appropriate personalized therapy with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, because not every CF patient shows the same response to these therapeutics [97]. The gene discussed is CFTR; the disease is cystic fibrosis.